# Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
Canonical URL: https://biopharmsignal.com/news/CBIO/gyre-therapeutics-announces-china-s-nmpa-grants-priority-review-to-the-nda-for-hydronidone-f351-for-chb-induced-liver-fibrosis-treatment
Ticker: CBIO
Company: Catalyst Biosciences
Source: Catalyst Biosciences
Published: 2026-03-17 11:00 EST
Original Source URL: https://ir.catalystbiosciences.com
## Summary

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (Nasdaq: GYRE), a San Diego-based innovative commercial stage biopharmaceutical company with operations in the United States and China, today announced that the Center for Drug Evaluation (CDE) of

## Article Body
SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre or Gyre Therapeutics) (Nasdaq: GYRE), a San Diego-based innovative commercial stage biopharmaceutical company with operations in the United States and China, today announced that the Center for Drug Evaluation (CDE) of
## Recent Company News
- 2026-05-12 20:06 EST — [Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-announces-nmpa-acceptance-of-new-drug-application-for-f351-hydronidone-for-chb-induced-liver-fibrosis-treatment) — Source: Catalyst Biosciences
- 2026-05-07 10:00 EST — [Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-reports-first-quarter-2026-results-and-provides-business-update) — Source: Catalyst Biosciences
- 2026-03-17 11:00 EST — [Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-announces-china-s-nmpa-grants-priority-review-to-the-nda-for-hydronidone-f351-for-chb-induced-liver-fibrosis-treatment) — Source: Catalyst Biosciences
- 2026-03-12 10:00 EST — [Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update) — Source: Catalyst Biosciences
- 2026-03-02 13:00 EST — [Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and Pipeline](https://biopharmsignal.com/news/CBIO/gyre-therapeutics-enters-into-agreement-to-acquire-cullgen-to-gain-targeted-protein-degradation-platform-and-pipeline) — Source: Catalyst Biosciences
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)